Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 30-37

  Viale, Pierluigi ^a   Giannella, Maddalena ^a   Tedeschi, Sara ^a   Lewis, Russell ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; GRAM-NEGATIVE BACTERIAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84937714393     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.07.001     Document Type: Review

References (64)

1. D.L. Paterson, W.C. Ko, A. Von Gottberg, S. Mohapatra, J.M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K.P. Klugman, R.A. Bonomo, and et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases Clin Infect Dis 39 2004 31 37
2. A. Endimiani, F. Luzzaro, G. Brigante, M. Perilli, G. Lombardi, G. Amicosante, G.M. Rossolini, and A. Toniolo Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases Antimicrob Agents Chemother 49 2005 2598 2605
3. M. Tumbarello, M. Sanguinetti, E. Montuori, E.M. Trecarichi, B. Posteraro, B. Fiori, R. Citton, T. D'Inzeo, G. Fadda, R. Cauda, and et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment Antimicrob Agents Chemother 51 2007 1987 1994
4. V.P. Chaubey, J.D. Pitout, B. Dalton, T. Ross, D.L. Church, D.B. Gregson, and K.B. Laupland Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae BMC Res Notes 3 2010 116
5. N. Girometti, R.E. Lewis, M. Giannella, S. Ambretti, M. Bartoletti, S. Tedeschi, F. Tumietto, F. Cristini, F. Trapani, P. Gaibani, and et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy Medicine (Baltimore) 93 2014 298 309
6. P.D. Tamma, J.H. Han, C. Rock, A.D. Harris, E. Lautenbach, A.J. Hsu, E. Avdic, and S.E. Cosgrove Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia Clin Infect Dis 60 2015 1319 1325
7. F. Perez, and R.A. Bonomo Editorial commentary: bloodstream infection caused by extended-spectrum beta-lactamase-producing gram-negative bacteria: how to define the best treatment regimen? Clin Infect Dis 60 2015 1326 1329
8. P.N. Harris, P.A. Tambyah, and D.L. Paterson beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 15 2015 475 485
9. J. Rodriguez-Bano, M.D. Navarro, P. Retamar, E. Picon, and A. Pascual Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts Clin Infect Dis 54 2012 167 174
10. P. Retamar, L. Lopez-Cerero, M.A. Muniain, A. Pascual, and J. Rodriguez-Bano Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli Antimicrob Agents Chemother 57 2013 3402 3404
11. K.Y. Lew, T.M. Ng, M. Tan, S.H. Tan, E.L. Lew, L.M. Ling, B. Ang, D. Lye, and C.B. Teng Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting J Antimicrob Chemother 70 2015 1219 1225
12. P.N. Harris, A.Y. Peleg, J. Iredell, P.R. Ingram, S. Miyakis, A.J. Stewardson, B.A. Rogers, E.S. McBryde, J.A. Roberts, J. Lipman, and et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial Trials 16 2015 24
13. K.A. Toussaint, and J.C. Gallagher Beta-lactam/beta-lactamase inhibitor combinations: from then to now Ann Pharmacother 49 2015 86 98
14. S.D. Lahiri, M.R. Johnstone, P.L. Ross, R.E. McLaughlin, N.B. Olivier, and R.A. Alm Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance Antimicrob Agents Chemother 58 2014 5704 5713
15. C. Lucasti, I. Popescu, M.K. Ramesh, J. Lipka, and C. Sable Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial J Antimicrob Chemother 68 2013 1183 1192
16. J.A. Vazquez, L.D. Gonzalez Patzan, D. Stricklin, D.D. Duttaroy, Z. Kreidly, J. Lipka, and C. Sable Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study Curr Med Res Opin 28 2012 1921 1931
17. C.C. Bulik, P.R. Tessier, R.A. Keel, C.A. Sutherland, and D.P. Nicolau In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms Antimicrob Agents Chemother 56 2012 544 549
18. M. Nguyen, G.A. Eschenauer, M. Bryan, K. O'Neil, E.Y. Furuya, P. Della-Latta, and C.J. Kubin Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes Diagn Microbiol Infect Dis 67 2010 180 184
19. E.A. Neuner, J.Y. Yeh, G.S. Hall, J. Sekeres, A. Endimiani, R.A. Bonomo, N.K. Shrestha, T.G. Fraser, and D. van Duin Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections Diagn Microbiol Infect Dis 69 2011 357 362
20. O. Zarkotou, S. Pournaras, P. Tselioti, V. Dragoumanos, V. Pitiriga, K. Ranellou, A. Prekates, K. Themeli-Digalaki, and A. Tsakris Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment Clin Microbiol Infect 17 2011 1798 1803
21. Z.A. Qureshi, D.L. Paterson, B.A. Potoski, M.C. Kilayko, G. Sandovsky, E. Sordillo, B. Polsky, J.M. Adams-Haduch, and Y. Doi Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens Antimicrob Agents Chemother 56 2012 2108 2113
22. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, A. Marchese, T. Spanu, S. Ambretti, F. Ginocchio, F. Cristini, and et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950
23. A. Capone, M. Giannella, D. Fortini, A. Giordano, M. Meledandri, M. Ballardini, M. Venditti, E. Bordi, D. Capozzi, M.P. Balice, and et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality Clin Microbiol Infect 19 2013 E23 E30
24. G.L. Daikos, S. Tsaousi, L.S. Tzouvelekis, I. Anyfantis, M. Psichogiou, A. Argyropoulou, I. Stefanou, V. Sypsa, V. Miriagou, M. Nepka, and et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems Antimicrob Agents Chemother 58 2014 2322 2328
25. M. Tumbarello, E.M. Trecarichi, F.G. De Rosa, M. Giannella, D.R. Giacobbe, M. Bassetti, A.R. Losito, M. Bartoletti, V. Del Bono, S. Corcione, and et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study J Antimicrob Chemother 70 2015 2133 2143
26. M. Paul, Y. Carmeli, E. Durante-Mangoni, J.W. Mouton, E. Tacconelli, U. Theuretzbacher, C. Mussini, and L. Leibovici Combination therapy for carbapenem-resistant Gram-negative bacteria J Antimicrob Chemother 69 2014 2305 2309
27. G. De Pascale, L. Montini, M. Pennisi, V. Bernini, R. Maviglia, G. Bello, T. Spanu, M. Tumbarello, and M. Antonelli High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria Crit Care 18 2014 R90
28. D. van Duin, E.D. Cober, S.S. Richter, F. Perez, M. Cline, K.S. Kaye, R.C. Kalayjian, R.A. Salata, S.R. Evans, V.G. Fowler Jr. , and et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance Clin Microbiol Infect 20 2014 O1117 O1120
29. M. Gonzalez-Padilla, J. Torre-Cisneros, F. Rivera-Espinar, A. Pontes-Moreno, L. Lopez-Cerero, A. Pascual, C. Natera, M. Rodriguez, I. Salcedo, F. Rodriguez-Lopez, and et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae J Antimicrob Chemother 70 2015 905 913
30. M. Monaco, T. Giani, M. Raffone, F. Arena, A. Garcia-Fernandez, S. Pollini, H. Grundmann, A. Pantosti, and G.M. Rossolini Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014 Euro Surveill 2014 19
31. C. Tascini, E. Tagliaferri, T. Giani, A. Leonildi, S. Flammini, B. Casini, R. Lewis, S. Ferranti, G.M. Rossolini, and F. Menichetti Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae Antimicrob Agents Chemother 57 2013 3990 3993
32. C.C. Bulik, and D.P. Nicolau Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae Antimicrob Agents Chemother 55 2011 3002 3004
33. H. Giamarellou, L. Galani, F. Baziaka, and I. Karaiskos Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae Antimicrob Agents Chemother 57 2013 2388 2390
34. R.K. Shields, M.H. Nguyen, B.A. Potoski, E.G. Press, L. Chen, B.N. Kreiswirth, L.G. Clarke, G.A. Eschenauer, and C.J. Clancy Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia Antimicrob Agents Chemother 59 2015 1797 1801
35. M. Hilf, V.L. Yu, J. Sharp, J.J. Zuravleff, J.A. Korvick, and R.R. Muder Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients Am J Med 87 1989 540 546
36. P.D. Tamma, S.E. Cosgrove, and L.L. Maragakis Combination therapy for treatment of infections with gramnegative bacteria Clin Microbiol Rev 25 2012 450 470
37. J. Garnacho-Montero, M. Sa-Borges, J. Sole-Violan, F. Barcenilla, A. Escoresca-Ortega, M. Ochoa, A. Cayuela, and J. Rello Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy Crit Care Med 35 2007 1888 1895
38. D.R. Bowers, Y.X. Liew, D.C. Lye, A.L. Kwa, L.Y. Hsu, and V.H. Tam Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia Antimicrob Agents Chemother 57 2013 1270 1274
39. C. Pena, C. Suarez, A. Ocampo-Sosa, J. Murillas, B. Almirante, V. Pomar, M. Aguilar, A. Granados, E. Calbo, J. Rodriguez-Bano, and et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort Clin Infect Dis 57 2013 208 216
40. L. Leibovici, M. Paul, O. Poznanski, M. Drucker, Z. Samra, H. Konigsberger, and S.D. Pitlik Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study Antimicrob Agents Chemother 41 1997 1127 1133
41. A. Kuikka, and V.V. Valtonen Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital Eur J Clin Microbiol Infect Dis 17 1998 701 708
42. L. Morata, N. Cobos-Trigueros, J.A. Martinez, A. Soriano, M. Almela, F. Marco, H. Sterzik, R. Nunez, C. Hernandez, and J. Mensa Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia Antimicrob Agents Chemother 56 2012 4833 4837
43. B. Planquette, J.F. Timsit, B.Y. Misset, C. Schwebel, E. Azoulay, C. Adrie, A. Vesin, S. Jamali, J.R. Zahar, B. Allaouchiche, and et al. Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure Am J Respir Crit Care Med 188 2013 69 76
44. P. Viale, and F. Pea What is the role of fluoroquinolones in intensive care? J Chemother 15 suppl 3 2003 5 10
45. A. Safarika, I. Galani, A. Pistiki, and E.J. Giamarellos-Bourboulis Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin Eur J Clin Microbiol Infect Dis 34 2015 317 323
46. D.J. Farrell, R.K. Flamm, H.S. Sader, and R.N. Jones Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012) Antimicrob Agents Chemother 57 2013 6305 6310
47. J.A. Viehman, M.H. Nguyen, and Y. Doi Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections Drugs 74 2014 1315 1333
48. Z.A. Qureshi, L.E. Hittle, J.A. O'Hara, J.I. Rivera, A. Syed, R.K. Shields, A.W. Pasculle, R.K. Ernst, and Y. Doi Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance Clin Infect Dis 60 2015 1295 1303
49. M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, D.E. Karageorgopoulos, A. Kapaskelis, D. Nikita, and A. Michalopoulos Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2010 194 199
50. R.K. Shields, C.J. Clancy, L.M. Gillis, E.J. Kwak, F.P. Silveira, R.C. Massih, G.A. Eschenauer, B.A. Potoski, and M.H. Nguyen Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients PLoS ONE 7 2012 e52349
51. A. Batirel, I.I. Balkan, O. Karabay, C. Agalar, S. Akalin, O. Alici, E. Alp, F.A. Altay, N. Altin, F. Arslan, and et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections Eur J Clin Microbiol Infect Dis 33 2014 1311 1322
52. L.E. Lopez-Cortes, and J. Rodriguez Bano Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort - authors' response J Antimicrob Chemother 69 2014 3167 3168
53. H. Aydemir, D. Akduman, N. Piskin, F. Comert, E. Horuz, A. Terzi, F. Kokturk, T. Ornek, and G. Celebi Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia Epidemiol Infect 141 2013 1214 1222
54. E. Durante-Mangoni, G. Signoriello, R. Andini, A. Mattei, M. De Cristoforo, P. Murino, M. Bassetti, P. Malacarne, N. Petrosillo, N. Galdieri, and et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial Clin Infect Dis 57 2013 349 358
55. J. Garnacho-Montero, R. Amaya-Villar, A. Gutierrez-Pizarraya, E. Espejo-Gutierrez de Tena, M.L. Artero-Gonzalez, Y. Corcia-Palomo, and J. Bautista-Paloma Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii Chemotherapy 59 2013 225 231
56. N. Petrosillo, M. Giannella, M. Antonelli, M. Antonini, B. Barsic, L. Belancic, A.C. Inkaya, G. De Pascale, E. Grilli, M. Tumbarello, and et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria Antimicrob Agents Chemother 58 2014 851 858
57. R. Sirijatuphat, and V. Thamlikitkul Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections Antimicrob Agents Chemother 58 2014 5598 5601
58. D.R. Nunley, G.S. Bauldoff, J.E. Mangino, and A.L. Pope-Harman Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients Lung 188 2010 381 385
59. A. Dalhoff Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis 34 2015 661 668
60. Q. Lu, C. Girardi, M. Zhang, B. Bouhemad, K. Louchahi, O. Petitjean, F. Wallet, M.H. Becquemin, G. Le Naour, C.H. Marquette, and et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa Intensive Care Med 36 2010 1147 1155
61. L.B. Palmer, and G.C. Smaldone Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit Am J Respir Crit Care Med 189 2014 1225 1233
62. F.G. Zampieri, A.P. Nassar Jr. , D. Gusmao-Flores, L.U. Taniguchi, A. Torres, and O.T. Ranzani Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis Crit Care 19 2015 150
63. A. Valachis, G. Samonis, and D.P. Kofteridis The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis Crit Care Med 43 2015 527 533
64. P. Rattanaumpawan, J. Lorsutthitham, P. Ungprasert, N. Angkasekwinai, and V. Thamlikitkul Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria J Antimicrob Chemother 65 2010 2645 2649